Synthesis, Crystal Structure and Interaction With DNA of N,N′-(Butane-1,4-Diyl)Bis(Guanidinium) Tetrachloroplatinate (II) by Bailly, Christian et al.
SYNTHESIS, CRYSTAL STRUCTURE AND INTERACTION WITH DNA OF
N,N’-(BUTANE-1,4-DIYL)BIS(GUANIDINIUM) TETRACHLOROPLATINATE (11)
Christian Bailly*, Bernard Viossat2, Xavier Labouze3, Georges Morgant3,4,
Carmella Saturnino5, Jean Charles Lancelota, Max RobbaS and Nguyen Huy Dunga
Laboratoire de Pharmacologie Antitumorale du Centre Oscar Lambret and INSERM U-124, Place
de Verdun, Lille, 2 Laboratoire de Chimie Gnrale, Facult Mixte de Mdecine et de Pharmacie,
Poitiers, 3 Laboratoire de Cristallochimie Bioinorganique, Facult de Pharmacie Paris XI, Ch&tenay-
Malabry, 4 Laboratoire de Biochimie, HSpital Armand Trousseau, AP-HP, Paris, and 5 Centre d’Etude
etde Recherche surle IVldicamentde Normandie, UFR des Sciences Pharmaceutiques, Caen, France
Correspondence and reprint requests E-mail: bailly@lille.inserm.fr FAX: (+33) 3 20 16 92 29
This paper is dedicated to the memory of Dr Daniel Perrine (deceased on May 25
th 1997) who
initiated our collaboration.
Abstract The design, synthesis, crystal structure and interaction with DNA of the N,N’-(butane-1,4-
diyl)bis(guanidinium) tetrachloroplatinate(ll) are described. Crystal data a 8.152(1 ), b 8.889(4),
c 10.700(3) ,/k, o 81.59(3), I 87.99(5), /= 78.48(6), V 752(1) A3 Z 2 space group P-1
The structure was refined to R 0.039 and Rw 0.046 from 1853 reflections (I > 3(I)). This
compound, named PtC4Gua, does not exhibit a center of symmetry and the center linker chain C(2)
C(3) C(4) C(5) is in gauche conformation. The cation is bisprotonated with the H attached to the
imine group of each terminal guanidinium function. The presence of the platinum moiety reinforces
the binding of the butane(bis)guanidinium structure with double stranded DNA as judged from
thermal denaturation studies and DNA unwinding experiments.
Introduction
Platinum complexes, like cis-diamminedichloroplatinum (11) (cisplatin) and carboplatin, are effective
antitumor agents used for the treatment of genitourinary and head and neck cancers [1]. Very
recently, oxaliplatin (1R,2R-diaminocyclohexanedicarboxylatoplatinum(ll)) has been recommended
in metastatic colon rectal cancer treatment with neither nephrotoxicity nor cross-resistance to
cisplatin [2]. The biological effects are attributed to the formation of adducts with DNA. Cisplatin-
induced bifunctional intrastrand cross-links between neighbouring purine base residues induce
marked conformational kinks in DNA. These lesions are considered relatively difficult to repair [3].
The severe side effects of cisplatin and the development of resistance have encouraged the
design of alternative platinum compounds with a broader spectrum of activity, in particular against
cisplatin-resistant cell lines. Over the last ten years, a large number of drugs containing the basic cis-
[PtX2(amine)2] motif were synthesized [3]. Dimers formed by linking the monofunctional platinum
species [Pt(dien)CI]+ by a tetramethylene linker exhibit a greatly enhanced ability for interstrand
cross-linking compared to cisplatin itself [4]. The bis(platinum) complex shown in Figure
represents a promising antitumor agent with a pronounced cytotoxic effect toward cell lines resistant
to cisplatin [5]. Recently, a novel bifunctional triplatinum(ll) complex, BBR 3464, was shown to
exhibit comparable or superior efficacity to cisplatin and is now entering phase clinical trials [6]. Its
structure can be described as two trans [PtCI(NH)] units linked by a central NH(CH)eNH- trans
Pt(NHa) NH(CH)eNH_ diamine chain.
Several non-classical platinum complexes that do not contain the aforementioned basic motif have
also been developed. Among them, the compound [rhodamine-123] PtCI4 was the first
tetrachloroplatinate (11) endowed with potent anticancer activity [7]. In addition, an (ethidium) PtCI4
conjugate showed reduced toxicity to mice compared to ethidium but equal trypanocidal activity [8].
These considerations prompted us to synthesize the bis(guanidinium) tetrachloroplatinate(ll) salt,
hereafter named PtC4Gua, which incorporates a (butane-1,4-diyl)bis(guanidinium) cation and PtCI4
as counteranion.
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Figure 1: Structure of some platinum(ll) compounds.
2 Results and discussion
2.1 Description of the N,N’-(butane-1,4-diyl)bis(guanidinium) tetrachloroplatinate (11) structure.
Distances and angles are reported in Table 1_ In the N,N’-(butane-l,4-diyl)bis(guanidinium)
tetrachloroplatinate (11)[C6H8N6]2/[PtCI,]
2 (fig. 2), the asymmetric unit consists of one square planar
[PtCI4]
2 anion and one N,N’-(butane-1,4-diyl)bis(guanidinium) cation.
Table Interatomic distances (.&) and angles (). s.d’s in parentheses refer to the last significant
digit.
a) distances b) angles
Pt(1) -C1(1) 2.308(2) C1(1) -Pt(1) -C1(2) 89.8(1)
Pt(1) -C1(2) 2.301(3) C1(1) -Pt(1) -C1(3) 177.71(9)
Pt(1) -C1(3) 2.303(2) C1(2) -Pt(1) -C1(3) 90.5(1)
Pt(1) -C1(4) 2.302(3) C1(1) -Pt(1) -C1(4) 90.9(1)
N(12) -C(11) 1.34(1) C1(2) -Pt(1) -C1(4) 177.7(1)
N(13) -C(11) 1.31(1) C1(3) -Pt(1) -C1(4) 89.0(1)
N(14) -C(1) 1.50(1) C(1) -N(14) -C(11) 125.0(9)
N(14) -C(11) 1.31(1) C(4) -N(24) -C(21) 122.3(10)
N(22) -C(21) 1.33(1) N(14) -C(1) -C(2) 111.3(9)
N(23) -C(21) 1.29(1) C(1) -C(2) -C(3) 113.0(9)
N(24) -C(4) 1.49(1 C(2) -C(3) -C(4) 110.8(1 O)
N(24) -C(21) 1.31 (1) N(24) -C(4) -C(3) 109.4(1 O)
C(1) -C(2) 1.54(2) N(12) -C(11) -N(13) 118.4(10)
C(2) -C(3) 1.53(1) N(12) -C(11) -N(14) 120.3(10)
C(3) -C(4) 1.48(2) N(13) -C(11) -N(14) 121.3(10)
N(22) -C(21) -N(23) 118.6(1 O)
N(22) -C(21) -N(24) 118.1 (1 O)
N(23) -C(21) -N(24) 123.2(1 O)
This cation does not exhibit an inversion center half away along the C(2)-C(3) bond and the central
linker chain C(1 C(2) C(3) C(4) exhibits a gauche conformation, as shown by the torsion angle
value of -64.14. In contrast, in the crystal structure of S,S’-(1,8-octanediyl)bis(thiouronium)-
tetrachloroplatinate(ll), the cation exhibits a centre of symmetry and packs in a mixed trans(t) and
gauche(g) conformation, with a tgtttttgt sequence [9]. However, in the S,S’-(1,4-
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butanediyl)bis(thiouronium) tetrachloroplatinate (ll),the cation exhibits an extended trans
configuration [10]. Moreover, in the title compound, the cation is bisprotonated with the H
attached to the imine group of each terminal guanidinium function and with the three equivalent C-N
bonds in the range from 1.31(1) to 1.34(1) A. The two guanidinium moieties are planar with the
C(11) and C(21) out-of-plane displacements of-0.01 and 0.02 ,&, respectively and the dihedral
angle is 20.4 between them. In the [PtCI4] counteranion, the platinum atom exhibits a quasi-ideal
square planar coordination, the distances being in the range 2.301(3)-2.308(2) A and the angles
89.01-90.9(1). There is an extensive hydrogen-bonding network involving the four chloride atoms
of each tetrachloroplatinate(ll) anion and hydrogen atoms in the different guanidinium moieties
(Table 2).
Ci2
CI4 iv
Figure 2 Perspective view of PtC4Gua generated by CAMERON using 50% probability ellipsoids
for the non-hydrogen atoms. The crystallographic labelling scheme is shown. The hydrogen bonds
are shown by dotted lines. SynTnetycode i" x, l+y, z ii -x, l-y, 1-z ;iii" 1-x,-1-y, -z ;iv" l+x,-l+y, z.
Table 2 Hydrogen bonds (,&,). E.s.d’s in parentheses refer to the last significant digit.
Distance (.) Angle (o)
N(12) -H(122) C1(2)’ 3.38(2) 35
N(13) -H(131) C1(1)’ 3.38(2) 46
N(14) -H(14) C1(3)" 3.36(1) 158
N(22) H(221) C1(4)"’ 3.31 (2) 140
N(22) -H(222) C1(4)
’v 3.38(1) 138
N(24) H(24) C1(1 )’" 3.36(1 69
Symmetry Code "i’x, l+y, z ;ii" -x, 1-y, 1-z ;iii" 1-x, -1-y, -z ;iv" l+x, -l+y, z
2.2 DNA binding
2.2.1 DNA thermal denaturation
The ability of the platinated compound PtC4Gua and its non-platinated analogue C4Gua to alter the
thermal denaturation profile of double stranded DNA was used as a first indication of their propensity
to bind to DNA.
The zTm values are collated in Table 3. A much larger increase in the Tm of nucleic acids is
observed with the platinated compound than with the Pt-free bisguanidine.
The stabilization of the DNA double helix by binding of the drug increases with increasing molar ratio
of drug to DNA-phosphate (D/P). We can conclude that the bisguanidinium chain promotes the
interaction with DNA and that the [PtCI4] anion contributes to reinforce the interaction with DNA.
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Table 3. Variation in melting temperature
C4Gua PtC4Gua
conc (#M) 10 20 0 20
(/Tm in C) poly (dA-dT)2 3.6 9.0 19.2 25.2
(ATm in C) calf thymus DNA 1.6 10.6 9.7 13.6
2.2.2 DNA double helix unwinding
We determined the capacity of the drug to unwind the double helix. The antitumor drug cisplatin
readily unwinds supercoiled DNA by about 13 corresponding to covalent crosslinking into the
double helix [11]. The local duplex unwinding is believed to be a major determinant in the
recognition of DNA damages by repair enzymes and therefore it may be essential to the biological
activity of the drug. Electrophoresis in native agarose gel was used to determine the unwinding
induced in pUC19 plasmid by PtC4Gua by monitoring the degree of supercoiling. This sensitive
method has been used previously to quantify the unwinding produced by cisplatin and a variety of
platinum complexes [12].
C4Gua PtC4Gua
102550Ct 2 5 102550Ct
,,..[
Figure 3 Unwinding of supercoiled,pUC19 plasmid DNA
, .i.i
-Rel by PtC,Gua. Sc, supercoiled DNA Rel, relaxed DNA.
As shown in iure a, the number ol suercoils in the lasmid is reduced uon addition of PtCGua
whereas ther is absolutely no eIIct with the analogue CGua lackin the latinum rous as
with (PtCI). Surcoild DN becomes rogrssivly rlax6 as the double helix is unwoun6 bg
PtCGua. When the suercoiled DNA comigratas with the nicRl rlaxad band, th DNA has been
Iullg relaxed. This coalescence oint is use6 to determine the amount of drug
complete removal o all suercoils rom the DNA and then to calculat the unwinding angle. Under
these con6itions ol the resent experiments, we calculated an unwindin anle of 8 ( for PtGGua
which is lower than the angle determined Ior cislatin (2 ()) but, however, it Ialls in the range
unwindin anles commonlg determined with latinated compounds [2]. Together with the I’m
measurements, these experiments leave no room for 6oubt that the latinum moiety of PtCGua
lags a significant role in the interaction with DN. The design ol small molecules containin a
tetrachlorolatinate(ll) center meg reresent a valuable aroach to the conception of new classes
drugs actin at th Ivl of NA.
3 Experimental
3.1. Synthesis
Reaction of 1,4-diaminobutane with 3,5-dimethylpyrazole-l-carboxamidine nitrate in ethanol under
reflux afforded N,N’-(butane-1,4-diyl)bis guanidinium nitrate (C,Gua) in a 71% yield.
H2N-(CH2)4-NH2 /7__
’CH3
+ 2 HaC -Ir
H2N’’NH
,HNO3
C4Gua I
NH. HN"._HN_(CH2)4_NH_C
+ 2 /t
’CH3
H3C-’MN-N
H
2+
80%
2NO, PtC4Gua
K2PtCI4
The diamidine was then dissolved in 1M HCI before adding K2PtCI4 in small portions. The solution
was heated for 2 hours at 60C and then cooled down. The desired platinum compound (PtC,Gua)
was obtained in a 80% yield by slow evaporation of the solution at room temperature.
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3.2 Structure determination of PtC4Gua [CeHaNe]+[PtCI4]
The refined cell constants and other relevant crystal data are presented in Table 4, together with
details of the intensity measurements. The crystal was mounted, using glass fibers, on an ENRAF-
NONIUS CAD4 diffractometer equipped with a graphite monochromator. The lattice parameters
were refined using 25 reflections. The data were collected using the o-2e scan technique and with
Mo K(z radiation 0.71073 ).
Table 4: Crystal data for the title compound.
Crystal Parameters
compound [CHN]+[PtCI4]
fw(g) 511.15
shape (colour) parallelepiped (orange)
size, mm 0.05, 0.08, 0.30
crystal system triclinic
space group P-1
a,A 8.152(1)
b, ,/k 8.889(4)
c,A 10.700(3)
o, 81.59(3) , 87.99(5)
7, 78.48(6)
V, A3 752(1)
Z 2
F(000) 480.26
p(calcd), g.cm"3 2.26
la (MoKo0, cm" 101.3
Data collection
Diffractometer Enraf-Nonius CAD4
rnonochromator graphite
radiation, ,& MoKo (X 0.71073)
Scan mode o0 20
temperature, K 291
20 range, deg 4.0< 20 <48
Absorption correction None
no. ofunique rflns 2351
reflections used 1853(1>3(I))
Refinement
R / Rw 0.039 / 0.049
Weighting Scheme Chebyshev
Coefficient Ar 3.30,-0.276,2.64
GOF 1.13
(m/O’)max 0.03
Apmin/Apmax (e. A3) -1.41/1.61
Number ofparameters 155
During the data collection, three intensity control reflections were monitored every two hours,
showing no loss of intensity. The data were corrected for Lorentz and polarisation effects. The
structure was solved by a combination of direct methods using SIR procedure [13] and heavy-atom
techniques and refined by full-matrix least-squares method based on F, using CRYSTALS [14]. No
absorption correction was applied as tR was estimated equal 0.3, where R is half the minimum
crystal dimension. Anisotropic displacement parameters were assigned to all non-H atoms. The
hydrogen atoms were introduced in calculated idealized positions (d(C-H) 0.96 A) and their atomic
coordinates were recalculated after each cycle.
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They were given isotropic thermal arameters 20% hi her P g than those of the carbon to which they are attached. Least-squares refinements were performed by minimizing the function ,%w(IFol-IFcl)’,
where Fo and Fo are the observed and calculated structure factors. The weighting scheme used in
the last refinement cycles was w w’[1-(zF/6(Fo)] where w’= 1/EnArTr(X) with 3 coefficients A for
the Chebyshev polynomial Armr(X where x was Fc/F.(max) [15]. Models reached convergence with
R (IIFoI-IFclI)/Z.(IFol) and Rw [w(IFol-IFcl)/F_.W(Fo), having values listed in Table 3. Criteria for a
satisfactory complete analysis were ratios of rms shift to standard deviation less than 0.1 and no
significant features in final difference maps. Details of data collection and refinement are given in
Table 4. Calculations were performed with a PC CRYSTALS package program. The drawings of the
molecules were generated using CAMERON [16]. The atomic scattering factors were taken from
International Tables for X-ray Crystallography [17].Fractional atomic coordinates and equivalent
isotropic thermal parameters were shown in table 5.
Table 5 Fractional atomic coordinates and equivalent isotropic thermal parameter U(eq). S. d’s in
parentheses refer to the last significant digit.
U(eq) is defined as the cube root of the product of the principal axes.
Atom x/a y/b z/c U(eq)
Pt(1) 0.23167(4) -0.28103(4) 0.27121(3) 0.0291
C1(1) 0.3462(4) -0.4587(3) 0.1393(2) 0.0473
C1(2) 0.2133(4) -0.4814(3) 0.4303(2) 0.0472
C1(3) 0.1071(3) -0.1032(3) 0.3993(2) 0.0461
C1(4) 0.2590(4) -0.0786(3) 0.1162(2) 0.0491
N(12) 0.583(1) 0.280(1) 0.3871(9) 0.0521
N(13) 0.428(1) 0.165(1) 0.272(1) 0.0571
N(14) 0.656(1) 0.018(1) 0.3804(9) 0.0489
N(22) 0.911(1) -0.799(1) 0.117(1) 0.0567
N(23) 1.007(1) -0.713(1) 0.283(1) 0.0534
N(24) 0.834(1) -0.545(1) 0.139(1) 0.0461
C(1) 0.651(1) -0.128(1) 0.328(1) 0.0429
C(2) 0.732(1) -0.126(1) 0.196(1) 0.0473
C(3) 0.723(1) -0.271(1) 0.136(1) 0.0527
C(4) 0.822(2) -0.412(2) 0.210(1) 0.0627
C(11) 0.555(1) 0.152(1) 0.347(1) 0.0422
C(21) 0.920(1) -0.683(1) 0.181(1) 0.0441
3.3 DNA thermal denaturation
We measured the change of the absorbance at 260 nm as a function of the temperature for both calf
thymus DNA (42% AT base pairs) and the synthetic polynucleotide poly(dA-dT) in the absence and
presence of the test drugs. The variation of the Tm of helix-to-coil transition of the two nucleic acids
were determined in the presence of 10 and 20lLtM drug using 20 l.tM DNA.
Tm measurements were performed in BP buffer pH 7.1 (6 mM NaHPO4, 2 mM NaH_PO4 using 20
#M DNA at 260 nm with a heating rate of lC/min. Each drug concentration was tested in duplicate.
Tm for DNA alone 42.5 and 58.4C for poly(dA-dT) and calf thymus DNA, respectively.
3.4 Unwinding of supercoiled pUC19 plasmid DNA by PtC4Gua.
The DNA (0.5 t.tg) was incubated with C4Gua or PtC,Gua at the indicated concentration (taM) for 3h at
37C before loading the samples on a 1% agarose gel. Control lanes Ct refer to the plasmid DNA
incubated without drug. After 2h electrophoresis, the gel was stained with ethidium bromide
(ll.tg/ml) then destained in water prior to being photographed under UV light.
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